Chimpanzee-origin adenovirus vectors as vaccine carriers.
Vaccines based on replication-defective adenoviral vectors are being developed for infectious agents and tumor-associated antigens. Early work focused on vaccines derived from a common human serotype of adenovirus, that is, adenovirus of the serotype 5 (AdHu5). Neutralizing antibodies against AdHu5 virus, present in a large percentage of the human population, dampen the efficacy of vaccines based on this carrier. To circumvent this problem, we generated vectors derived from chimpanzee adenoviruses. Here we describe some basic parameters of vectors derived from chimpanzee adenoviruses C68 and C7, including growth characteristics, yields of infectious particles, effects of additional deletions in E3 and E4 and lengths of the inserted foreign sequence as they relate to the suitability for their eventual development as vaccine carriers for clinical use.
Tatsis
N
N
Immunology Program, Wistar Institute, Philadelphia, PA 19104, USA.
Tesema
L
L
Robinson
E R
ER
Giles-Davis
W
W
McCoy
K
K
Gao
G P
GP
Wilson
J M
JM
Ertl
H C J
HC
D000256:Adenoviridae / Q000235:genetics*; D000257:Adenoviridae Infections / Q000276:immunology; D000818:Animals; D000941:Antigens / Q000276:immunology; D019149:Bioreactors; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002460:Cell Line; D005260:Female; D005818:Genetic Engineering; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics*; D015151:Immunoblotting; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D002679:Pan troglodytes / Q000821:virology; D019076:Transgenes; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics*
D000941:Antigens; D014765:Viral Vaccines